var data={"title":"Flucytosine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Flucytosine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6204?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">see &quot;Flucytosine: Drug information&quot;</a> and <a href=\"topic.htm?path=flucytosine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Flucytosine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708774\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Monitoring:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Use with extreme caution in patients with renal impairment. Close monitoring of hematologic, renal, and hepatic status of all patients is essential.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171786\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ancobon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047411\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antifungal Agent, Systemic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442535\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Administer in combination with amphotericin B or another susceptible antifungal to prevent development of resistance:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection</b> (Bradley 2016): Limited data available: Oral: Initial:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight &lt;1 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &le;14 days: 75 mg/kg/<b>day</b> divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA 15 to 28 days: 75 mg/kg/<b>day</b> divided every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight 1 to 2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &le;7 days: 75 mg/kg/day divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA 8 to 28 days: 75 mg/kg/day divided every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight &gt;2 kg, PNA &le;60 days: 75 mg/kg/<b>day</b> divided every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Monitoring of serum concentrations recommended; reported dosing range: 25 to 100 mg/kg/<b>day</b> in divided doses every 6 to 24 hours (Baley 1990; Fernandez 2000; Marr 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidal meningitis</b>: Limited data available: Oral: 100 mg/kg/<b>day</b> in divided doses every 6 to 8 hours in combination with amphotericin B; monitoring of serum concentrations should be considered; reported range: 75 to 100 mg/kg/day; dosing based on a retrospective study and case reports (n=9) including premature neonates (GA: 24 to 28 weeks; PMA at treatment: 26 to 29 weeks); treatment duration in some cases was up to 6 weeks (Fernandez 2000; IDSA [Pappas 2016]; Marr 1994; Pahud 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047403\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">see &quot;Flucytosine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In general, administer in combination with amphotericin B or another susceptible antifungal due to development of resistance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infections:</b> Infants, Children, and Adolescents: Oral: 50 to 150 mg/kg/day in divided doses every 6 hours (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Aspergillosis, endocarditis: </b>Limited data available: Children and Adolescents: Oral: 37.5 mg/kg/dose every 6 hours in combination with amphotericin B (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chorioretinitis:</i> Infants, Children, and Adolescents: Oral: 25 mg/kg/dose every 6 hours in combination with amphotericin B (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CNS disease, treatment:</i> Infants, Children, and Adolescents: Oral: 25 mg/kg/dose every 6 hours in combination with amphotericin B (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Endocarditis or implanted cardiovascular device: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: Oral: 25 mg/kg/dose every 6 hours in combination with amphotericin B; valve replacement or removal of hardware is strongly recommended (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: Oral: 25 to 37.5 mg/kg/dose every 6 hours in combination with amphotericin B; valve replacement or removal of hardware is strongly recommended (AHA [Baltimore 2015]; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Urinary tract infection:</i> Infants, Children, and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Cystitis, symptomatic: 25 mg/kg/dose every 6 hours for 7 to 10 days (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pyelonephritis: 25 mg/kg/dose every 6 hours for 2 weeks with or without amphotericin B (IDSA [Pappas 2016]); if fungal balls present, use in combination with amphotericin B and treatment duration should be until symptom resolution and clear urine culture</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cryptococcal disease; disseminated (including CNS disease); treatment (independent of HIV status):</b> Infants, Children, and Adolescents: Oral: 25 mg/kg/dose every 6 hours in combination with amphotericin B or fluconazole; minimum treatment duration: &ge;2 weeks; full treatment duration dependent upon: HIV status, source of infection and concomitant antifungal therapy (HHS [OI pediatric 2013]; HHS [OI Adult 2015]; Perfect 2010; Tunkel 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> Oral: 50 to 150 mg/kg/day in divided doses every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis:</b> Oral: 100 mg/kg/day in 3 or 4 divided doses (with amphotericin B) for at least 4 to 6 weeks after valve replacement (Gould 2012; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cryptococcal meningitis, treatment:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Non-HIV-infected:</i> Induction: 25 mg/kg/dose (with amphotericin B) every 6 hours for at least 4 weeks; if clinical improvement, may discontinue both amphotericin and flucytosine and follow with an extended course of fluconazole (IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-infected: </i>Induction: 25 mg/kg/dose (with an amphotericin B formulation [liposomal amphotericin B is preferred]) every 6 hours for at least 2 weeks (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Monitor serum concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Aronoff 2007: Infants, Children, and non-HIV-exposed/-positive Adolescents: Based on a usual dose of 100 to 150 mg/kg/day divided every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment recommended</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 25 to 37.5 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 25 to 37.5 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 25 to 37.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis or peritoneal dialysis: 25 to 37.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy: 25 to 37.5 mg/kg/dose every 8 hours; monitor serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HHS [OI adult] 2015: HIV-exposed/-positive: Adolescents: Based on a usual dose of 25 mg/kg every 6 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;40 mL/minute: No adjustment recommended</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 20 to 40 mL/minute: 25 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to &lt;20 mL/minute: 25 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: 25 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Administer dose after hemodialysis: 25 to 50 mg/kg every 48 to 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: There are no dosage adjustments provided in the manufacturer's labeling. <b>Note:</b> Manufacturer recommends dose reduction; the following guidelines have been used by some clinicians</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HIV-exposed/-positive: Based on dose of 25 mg/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;40 mL/minute: No dosage adjustment recommended (Perfect 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 20 to 40 mL/minute: 50% of standard dose every 6 hours (Perfect 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 20 mL/minute: 25% of standard dose every 6 hours (Perfect 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ESRD on intermittent hemodialysis (IHD): 25 to 50 mg/kg every 48 to 72 hours; administer dose after hemodialysis (Drew 1999; HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-exposed/-positive (HHS [OI adult 2015]): Based on a usual dose of 25 mg/kg every 6 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;40 mL/minute: No adjustment recommended</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 20 to 40 mL/minute: 25 mg/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to &le;20 mL/minute: 25 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: 25 mg/kg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ESRD on intermittent hemodialysis (IHD): 25 to 50 mg/kg every 48 to 72 hours; administer dose after hemodialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, flucytosine has minimal hepatic metabolism; use caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171760\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ancobon: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171744\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047416\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer around-the-clock to promote less variation in peak and trough serum levels; to avoid nausea and vomiting, administer a few capsules at a time over 15 minutes until full dose is taken.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171781\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at room temperature of 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047415\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of serious infections caused by susceptible strains of Candida (septicemia, endocarditis, pulmonary, urinary tract infections) and/or Cryptococcus (meningitis, pulmonary, septicemia, urinary  tract infections) in combination with amphotericin B (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171828\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flucytosine may be confused with fludarabine, fluorouracil </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ancobon may be confused with Oncovin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171826\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiotoxicity, chest pain, ventricular dysfunction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Ataxia, confusion, fatigue, hallucination, headache, paresthesia, parkinsonian-like syndrome, peripheral neuropathy, psychosis, sedation, seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin photosensitivity, skin rash, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypoglycemia, hypokalemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, diarrhea, duodenal ulcer, enterocolitis, gastrointestinal hemorrhage, nausea, ulcerative colitis, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Azotemia, crystalluria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, anemia, aplastic anemia, bone marrow aplasia, eosinophilia, leukopenia, pancytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic injury (acute), hepatic insufficiency, hepatic necrosis, increased liver enzymes, increased serum bilirubin, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Hearing loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171769\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to flucytosine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171748\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematologic disease: Use with caution in patients with bone marrow depression, hematologic disease or who have been treated with radiation or drugs that suppress the bone marrow; bone marrow toxicity may be irreversible. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; hepatotoxicity may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: <b>[US Boxed Warning]: Use with extreme caution in patients with renal dysfunction;</b> dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Monitoring: <b>[US Boxed Warning]: Closely monitor hematologic, renal, and hepatic status.</b> Hepatotoxicity and bone marrow toxicity appear to be dose related; monitor levels closely and adjust dose accordingly. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Monotherapy: Avoid use as monotherapy; resistance rapidly develops.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25820041\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Serum flucytosine concentrations are highly variable in neonates; monitor closely (Pasqualotte 2007); serum concentrations tended to be higher in children &lt;12 years of age; monitor closely (Soltani 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299342\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171753\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13304&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cytarabine (Conventional): May diminish the therapeutic effect of Flucytosine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gimeracil: May increase serum concentrations of the active metabolite(s) of Flucytosine. Specifically, gimeracil may increase concentrations of fluorouracil.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171782\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases the rate, but not the extent of absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171772\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Flucytosine is metabolized to fluorouracil which may cause adverse events if administered during pregnancy; refer to the Fluorouracil (Systemic) monograph for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047410\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prior to therapy: Serum electrolytes (especially potassium), CBC with differential, BUN, and creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">During therapy: Serum electrolytes, creatinine, BUN, alkaline phosphatase, AST, ALT, CBC, platelet count; serum flucytosine concentrations</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047414\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic: Trough: 25 to 50 mcg/mL; peak: 50 to 100 mcg/mL; peak concentrations should not exceed 100 mcg/mL to avoid bone marrow toxicity and hepatotoxicity; for patients who are HIV-exposed/-positive a peak concentration of 40 to 60 mcg/mL is recommended for infants and children (HHS [OI pediatric 2013]) and for adolescents and adults a peak of 30 to 80 mcg/mL is recommended (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trough: Draw just prior to dose administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peak: Draw 2 hours after an oral dose administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171747\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Penetrates fungal cells and is converted to fluorouracil which competes with uracil interfering with fungal RNA and protein synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171768\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid; serum concentrations are highly variable in neonates; monitor closely (Pasqualotto 2007); serum concentrations tended to be higher in children &lt;12 years of age; monitor closely (Soltani 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Into CSF, aqueous humor, joints, peritoneal fluid; V<sub>d</sub>: 0.6 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 3% to 4%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Minimally hepatic; deaminated both in yeasts and possibly via gut bacteria to 5-fluorouracil</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 78% to 89%; decreased in neonates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: 4 to 34 hours (Baley 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 7.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 2 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Anuria: 85 hours (range: 30 to 250)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD): 75 to 200 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: ~1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: 2.5 &plusmn; 1.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: ~1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&gt;90% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171767\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;\">\n      <b>50 mg/mL Oral Suspension (ASHP standard concentration) </b>(ASHP 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 50 mg/mL oral suspension may be made with capsules and OraPlus and OraSweet. Mix 30 mL of OraPlus and 30 mL of OraSweet together in a separate container. Empty the contents of six 500 mg capsules in a mortar; add 15 mL portion of the vehicle mixture and triturate. Transfer mixture to a 60 mL (2 ounce) amber prescription bottle. Rinse the mortar with an additional 15 mL of vehicle mixture and pour into the amber bottle. Repeat rinsing procedure until a final bottle volume of 60 mL is achieved. Label the bottle &quot;shake well.&quot; Stable for 90 days at 3&deg;C to 5&deg;C (37&deg;F to 41&deg;F) or 23&deg;C to 25&deg;C (73&deg;F to 77&deg;F).</p>\n    <div class=\"reference\">VandenBussche HL, Johnson CE, Yun J, et al. Stability of flucytosine 50 mg/mL in extemporaneous oral liquid formulations. <i>Am J Health Syst Pharm</i>. 2002;93(19):1853-1855.<span class=\"pubmed-id\">12374070</span></div>\r\n\n    <p style=\"text-indent:0em;\">\n      <b>10 mg/mL Oral Suspension</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 10 mg/mL oral suspension may be made with capsules and distilled water. Empty the contents of ten 500 mg capsules in a mortar; add small portions of distilled water and mix to a uniform paste. Mix while adding distilled water in incremental proportions to <b>almost</b> 500 mL; transfer to a 500 mL volumetric flask, rinse mortar several times with distilled water, and add sufficient quantity of distilled water to make 500 mL. Store in glass or plastic prescription bottles and label &quot;shake well&quot;. Stable for 70 days refrigerated and 14 days at room temperature.</p>\n    <div class=\"reference\">Wintermeyer SM and Nahata MC. Stability of Flucytosine in an Extemporaneously Compounded Oral Liquid. <i>Am J Health Syst Pharm</i>. 1996;53(4):407-409.<span class=\"pubmed-id\">8673661</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171771\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Ancobon Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $9,221.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $17,843.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Flucytosine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $8,206.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $15,880.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038617\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alcobon (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, NZ, OM, SA, SY, YE);</li>\n      <li>Ancobon (HK);</li>\n      <li>Ancotil (AE, AT, AU, BG, BH, BR, CH, CY, CZ, DE, DK, EG, FR, GB, GR, HR, IE, IL, IQ, IR, IT, JO, KW, LB, LY, NL, NO, OM, PL, QA, SA, SE, SG, SY, YE);</li>\n      <li>Ancotyl (RU);</li>\n      <li>Cocol (JP);</li>\n      <li>Flusine (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baley JE, Meyers C, Kliegman RM, et al, &ldquo;Pharmacokinetics, Outcome of Treatment, and Toxic Effects of Amphotericin B and 5-Fluorocytosine in Neonates,&rdquo; <i>J Pediatr</i>, 1990, 116(5):791-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/2329429 /pubmed\" target=\"_blank\" id=\"2329429 \">2329429 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Cantey JB, Kimberlin DK, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 22nd ed. American Academy of Pediatrics; 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drew RH, Perfect JR. Flucytosine. In: Yu VL, Merigan TC, Barriere SL, eds. <i>Antimicrobial therapy and vaccines</i>. Baltimore, MD: Williams and Wilkins; 1999:1170-1184.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fernandez M, Moylett EH, Noyola DE, et al, &quot;Candidal Meningitis in Neonates: A 10-Year Review,&quot; <i>Clin Infect Dis</i>, 2000, 31(2):458-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/10987705/pubmed\" target=\"_blank\" id=\"10987705\">10987705</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &quot;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&quot; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from  the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. December 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed March 17, 2016</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marr B, Gross S, Cunningham C, et al, &quot;Candidal Sepsis and Meningitis in a Very-Low-Birth-Weight Infant Successfully Treated With Fluconazole and Flucytosine,&quot; <i>Clin Infect Dis</i>, 1994, 19(4):795-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/7803656/pubmed\" target=\"_blank\" id=\"7803656\">7803656</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pahud BA, Greenhow TL, Piecuch B, et al, &quot;Preterm Neonates With Candidal Brain Microabscesses: A Case Series,&quot; <i>J Perinatol</i>, 2009, 29(4):323-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/19325555/pubmed\" target=\"_blank\" id=\"19325555\">19325555</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/26679628/pubmed\" target=\"_blank\" id=\"26679628\">26679628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasqualotto AC, Howard SJ, Moore CB, et al, &quot;Flucytosine Therapeutic Monitoring: 15 Years Experience From the UK,&quot; <i>J Antimicrob Chemother</i>, 2007, 59(4):791-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/17339279/pubmed\" target=\"_blank\" id=\"17339279\">17339279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perfect JR, Dismukes WE, Dromer F, et al, &quot;Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2010, 50(3):291-322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/20047480/pubmed\" target=\"_blank\" id=\"20047480\">20047480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soltani M, Tobin CM, Bowker KE, et al, &quot;Evidence of Excessive Concentrations of 5-Flucytosine in Children Aged Below 12 Years: A 12-Year Review of Serum Concentrations From a UK Clinical Assay Reference Laboratory,&quot; <i>Int J Antimicrob Agents</i>, 2006, 28(6):574-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/17085019/pubmed\" target=\"_blank\" id=\"17085019\">17085019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Glaser CA, Bloch KC, et al, &quot;The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2008, 47(3):303-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-pediatric-drug-information/abstract-text/18582201/pubmed\" target=\"_blank\" id=\"18582201\">18582201</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13304 Version 109.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708774\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F171786\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047411\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442535\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047403\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F171760\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F171744\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047416\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F171781\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047415\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F171828\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F171826\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F171769\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F171748\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25820041\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299342\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F171753\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F171782\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F171772\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047410\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1047414\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F171747\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F171768\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F171767\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F171771\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038617\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13304|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">Flucytosine: Drug information</a></li><li><a href=\"topic.htm?path=flucytosine-patient-drug-information\" class=\"drug drug_patient\">Flucytosine: Patient drug information</a></li></ul></div></div>","javascript":null}